Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B - 08/03/17
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
Liver cancer ranks as the second leading cause of cancer-related mortality in man worldwide, and hepatocellular carcinoma (HCC) is the most prevalent malignant neoplasm of the liver. The sensitivity of alpha-fetoprotein (AFP) as an HCC diagnostic marker for HCC diagnosis is 39–65%, and one-third patients with HCC are missed using AFP. New biomarkers are needed to diagnose HCC at an earlier stage and to individualize treatment strategies. Hepatocellular carcinoma suppressor 1 (HCCS1) is a newly identified liver tumor suppressor gene.
Objective |
Our study evaluated the diagnostic value of serum HCCS1 promoter methylation in patients with HCC associated with hepatitis B.
Methods |
We determined the methylation status of serum HCCS1 promoter in 120 patients with HCC, 146 patients with chronic hepatitis B (CHB) and 27 healthy controls (HCs) by methylation-specific polymerase chain reaction (MSP). Evaluation of a cohort with 63 patients with HCC and 44 patients with CHB was set as a validation dataset.
Results |
The frequency of HCCS1 promoter methylation in patients with HCC was significantly higher than that in patients with CHB (P<0.001) and HCs (P<0.001), and was associated with tumor node-metastasis (TNM) stage (P=0.01). The sensitivity of serum HCCS1 promoter methylation for discriminating patients with HCC from CHB was 62.5% and that of AFP alone was 55%. Notably, the sensitivity of serum HCCS1 promoter methylation plus AFP level was 81.7%.
Conclusion |
HCCS1 has potential as a biomarker for diagnosis and prognosis of patients with HCC.
Le texte complet de cet article est disponible en PDF.Abbreviations : HCCS1, HCC, AFP, CHB, HCs, MSP, TNM, US, MRI, CT, cfDNA, AASLD, HBsAg, HCV, HIV, NAFLD, AUC, ROC
Plan
Vol 41 - N° 2
P. 171-180 - mars 2017 Retour au numéro
Article précédent
- Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma
- Weijie Ma, Haitao Wang, Wei Jing, Fuling Zhou, Lei Chang, Zhenfei Hong, Hailing Liu, Zhisu Liu, Yufeng Yuan
- Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment
- Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Hee Jung Wang, Bong Wan Kim, Jung-Dong Lee, Dae Yong Kang, Ji Hyun Kim, Yang Min Jae, Jae Chul Hwang, Sung Jae Shin, Kee Myung Lee, Sung Won Cho, Jae Youn Cheong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?